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lation 0.81). Test-retest reliability was also high for all items of
the RDQ (reliability coefﬁcient > 0.9) and the readiness for dis-
charge status (tetrachoric correlation 0.82). Overall, 84% of the
raters agreed that the RDQ was useful in assessing patients’
readiness for discharge. Evidence of good construct validity
included signiﬁcant correlations with PANSS total and factor
scores, and a signiﬁcant relationship with actual discharge. Sig-
niﬁcantly more patients with symptom improvement were
judged ready for discharge (compared to those without symptom
improvement), indicating that the RDQ was responsive to
change over time. CONCLUSIONS: The RDQ has favorable
reliability and validity properties, and is an easy to use instru-
ment for assessing readiness for discharge of inpatients with
schizophrenia. The RDQ can be a useful tool in research settings,
as it provides a measure of the effects of an intervention on dis-
charge, independent of socio-economic inﬂuences.
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OBJECTIVES: The use of concomitant antipsychotics and other
psychotropics and the costs of polypharmacy in patients ran-
domized to risperidone or quetiapine were examined in a
prospective double-blind study. METHODS: Subjects were
patients with an acute exacerbation of schizophrenia or schizoaf-
fective disorder. In a 14-day phase, patients were randomized to
risperidone, quetiapine, or placebo monotherapy. In the follow-
ing 28-day additive-therapy phase, clinicians were allowed to
add antipsychotics or other psychotropics (including antidepres-
sants, anxiolytics, mood stabilizers and sedative/hypnotics).
Doses of risperidone or quetiapine were ﬁxed in the additive
therapy phase. RESULTS: Mean (±SD) doses at monotherapy
endpoint were 4.7 ± 0.9mg/day of risperidone and 579.5 ± 128.9
mg/day of quetiapine. Among 133 patients randomized to
risperidone, 33% received additional antipsychotics and 36%
received one or more psychotropics (including antipsychotics).
In the quetiapine group (N = 122), 53% and 53% received addi-
tional antipsychotics or psychotropics, respectively (P < 0.005 vs.
risperidone in both). In the placebo group, 57% received antipsy-
chotics and 62% psychotropics. The relative risk (quetiapine vs.
risperidone) for antipsychotic polypharmacy was 1.90 (95% CI
1.29–2.80). Improvements in PANSS total scores were signiﬁ-
cantly greater in patients receiving risperidone than quetiapine
or placebo at monotherapy endpoint (P < 0.001) and signiﬁ-
cantly greater with risperidone than placebo at the additive-
therapy endpoint (P < 0.01); quetiapine–placebo differences were
not signiﬁcant. The mean costs of antipsychotic polypharmacy
(for the duration of the additive-therapy phase) per randomized
patient were $57.03 in the risperidone group and $101.64 in the
quetiapine group (P < 0.05). The costs of the primary antipsy-
chotic plus the additional antipsychotics were $354,339 in the
risperidone group and $524,319 in the quetiapine group. CON-
CLUSIONS: The results conﬁrm earlier observations of higher
rates of polypharmacy with quetiapine than with risperidone.
These ﬁndings suggest that differential costs associated with
polypharmacy can be substantial.
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OBJECTIVE: This study aims to conduct a systematic review on
the literature concerning relapse and non-adherence in schizo-
phrenia patients in eight countries (Australia, Canada, France,
Germany, Italy, Spain, UK, and US). METHODS: As of Sep-
tember, 2004, a literature search was performed in a number of
databases including MEDLINE (1966–2004), EMBASE
(1980–2004), PsycINFO (1967–2004), Cumulative Index to
Nursing and Allied Health Literature (1980–2004) and other
health technology assessment databases. Of the 1000 retrieved
articles, around half were eventually reviewed in full text.
RESULTS: Although deﬁnitions and measures of adherence and
relapse between studies were very diverse, the rate of relapse in
schizophrenia appeared to be from 40% to 55% for patients not
taking the medication, and 14% to 30% for stabilized patients
maintained on medication. Conventional antipsychotics tended
to have higher rates of relapse than atypical antipsychotics. Most
relapses tended to occur within the ﬁrst year and, as such, many
studies had a short follow-up period. The medication adherence
rate for patients with schizophrenia ranged from 20% to 90%.
This review has found that adherence is affected by environ-
mental factors (e.g. social support), medication factors (e.g. side
effects or lack of efﬁcacy), doctor-patient relationship (e.g. lack
of knowledge concerning the illness), forgetfulness, and treat-
ment factors (e.g. medication regimes that are too complex).
There was substantial evidence that depot medication aids
patient adherence. Because current depot medications are avail-
able for conventional antipsychotics and risperidone, it was sug-
gested that considerable advantages may be observed when more
atypical antipsychotics are used in depot form. CONCLUSION:
Relapse and non-adherence to antipsychotic agents in schizo-
phrenia patients are quite prevalent and associated with adverse
consequences. Furthermore, because treatment adherence
appears to be strongly linked with relapse in schizophrenia, it is
important that treatment interventions continue to address the
problem of medication non-adherence.
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OBJECTIVES: This study estimates the 2002 annual prevalence
of schizophrenia in the US based on administrative claims data
analyses and a comprehensive literature review. METHODS:
The population-speciﬁc annual prevalence rates of schizophrenia
in the US were estimated separately for privately insured, gov-
ernment insured (Medicare, Medicaid), and uninsured popula-
tions. The 2002 annual prevalence for privately insured
individuals was calculated based on a de-identiﬁed administra-
tive claims database of approximately 3.0 million privately
insured beneﬁciaries covering the period from 1999 to 2003. 
The 2002 prevalence of Medicaid enrollees was calculated 
from Medi-Cal claims covering the period from 2000–2002. The
2002 schizophrenia prevalence in Medicare population was cal-
culated as a weighted average of the prevalence rates of Medic-
aid/Medicare dual eligibles and private insurance program
enrollees over 65. Published statistics were used to estimate the
prevalence of schizophrenia in the uninsured population. Finally,
